FY2024 EPS Estimate for Delcath Systems Raised by Analyst

Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) - Analysts at HC Wainwright upped their FY2024 EPS estimates for shares of Delcath Systems in a research note issued to investors on Monday, November 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.90) for the year, up from their prior forecast of ($1.18). HC Wainwright has a "Buy" rating and a $22.00 price target on the stock. The consensus estimate for Delcath Systems' current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Delcath Systems' Q4 2024 earnings at ($0.10) EPS, Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($0.87) EPS, FY2026 earnings at ($0.23) EPS and FY2027 earnings at $0.76 EPS.

A number of other equities research analysts have also recently commented on DCTH. Canaccord Genuity Group reissued a "buy" rating and issued a $21.00 target price on shares of Delcath Systems in a research note on Friday, October 18th. StockNews.com upgraded shares of Delcath Systems from a "sell" rating to a "hold" rating in a research note on Friday, October 25th. Finally, Stephens reiterated a "buy" rating on shares of Delcath Systems in a report on Friday, October 18th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Delcath Systems has a consensus rating of "Moderate Buy" and an average target price of $21.50.

Delcath Systems Stock Performance

Shares of DCTH traded up $0.05 during mid-day trading on Thursday, reaching $9.46. The company had a trading volume of 134,459 shares, compared to its average volume of 272,217. The company has a market capitalization of $302.44 million, a price-to-earnings ratio of -6.97 and a beta of 0.75. The firm has a 50-day moving average price of $9.71 and a 200 day moving average price of $8.43. Delcath Systems has a 52 week low of $2.30 and a 52 week high of $12.88.

Institutional Trading of Delcath Systems

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in Delcath Systems by 31.0% in the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company's stock worth $3,261,000 after buying an additional 161,678 shares in the last quarter. BVF Inc. IL raised its stake in Delcath Systems by 23.1% during the 1st quarter. BVF Inc. IL now owns 1,202,067 shares of the company's stock valued at $5,734,000 after purchasing an additional 225,918 shares during the period. Levin Capital Strategies L.P. raised its stake in Delcath Systems by 12.2% during the 1st quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company's stock valued at $262,000 after purchasing an additional 5,969 shares during the period. Rosalind Advisors Inc. lifted its holdings in Delcath Systems by 155.1% in the 2nd quarter. Rosalind Advisors Inc. now owns 2,650,389 shares of the company's stock worth $22,184,000 after purchasing an additional 1,611,561 shares in the last quarter. Finally, Legato Capital Management LLC bought a new position in Delcath Systems in the 2nd quarter worth approximately $966,000. 61.12% of the stock is currently owned by institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.